With an estimated 1.5m Americans being diagnosed with cancer this year alone, and an estimated half a million Americans will die because of cancer, it is little wonder why people are looking for alternatives to the traditional chemotherapy treatments usually recommended by their health practitioners which kills all cells, not just cancer cells.
According to a cancer researcher and Assistant Professor in the Division of Gynecologic Oncology at the State University of New York (SUNY) – Dr Ehsan Sarafraz-Yazdi, PNC-27 is a tiny, non-toxic protein molecule that attaches to cancer cells and causes them to die. According to PNC-27’s website, it was originally created to fight HIV by Dr Matthew Pincus and Dr Josef Michl. It was later discovered that PNC-27 would attach to and kill cancer cells, leaving healthy cells to thrive. It is most effective when used in conjunction with immune system boosters, proper hydration, and a vegan or near-vegan diet that avoids sugars and red meat.
About Dr Sarafraz-Yazdi
Dr Sarafraz-Yazdi is a highly educated cancer researcher who received his Masters in Science in Genetics from the University of Birmingham and the Imperial College of London (UK), and received his Ph.D. in Cellular and Molecular Biology from SUNY. His research in the field of anti-cancer drug design has been recognised by the 2011 Furchgott Award for Excellence in Research, a very prestigious award in the area of research. He has had several of his inventions patented (which you can find out more here) with his most recent patent is a method of treating cancer through administering a therapeutically effective amount of a composition which includes a HDM-2 binding component, and a membrance resident component being bound together.
Patents and Studies on PNC-27
In his TEDx talk (video available at the bottom of this article) which he gave at Connecticut College in 2012, Dr Sarafraz-Yazdi talks about PNC-27’s advantages over chemotherapy – that it:
- is a targeted form of therapy – highly selective damage only to rapidly dividing, cancerous cells
- has its own built-in delivery mechanism
- is a highly unique and effective method to kill cancer cells
- has no effect on other bodily systems (immune, digestive, respiratory, etc.)
The patents filed on PNC-27 cites that when properly administered, PNC-27 puts cancer on the defensive, resulting in outcomes that include significant pain reduction and, in many cases, lengthen one’s life. And there are multiple papers and studies which have been produced about PNC-27.
Laboratory research also began to look at targeted cancer therapies using proteins from the HDM-2 binding site in 2006. Although PNC-27 had not been discovered yet, the 2006 study of the protein and peptide sequence, later called PNC-27, reported that “[they] have found that these peptides induce 100 percent tumor cell necrosis, not apoptosis, in 13 different human cancer cell lines but have no effect on normal pancreatic acinar cells, breast epithelial cells, and human stem cells.”
Studies such as The Annals of Clinical and Laboratory Science which looked at the effectiveness of PNC-27 against human leukemia cell lines (K562) concluded that “PNC-27 is selectively cytotoxic to K562 cells, inducing nearly 100 percent cell killing…”; and one published in the Journal of Chemotherapy and Pharmacology which looked at PNC-27’s effect on breast cancer cells concluded that “PNC-27 induces cancer cell membrane lysis…”
The US Food and Drug Administration (FDA) has just issued a warning to consumers not to purchase, or use PNC-27 as a treatment or cure for cancer. An FDA laboratory discovered that the bacteria – Variovorax paradoxus in a PNC-27 solution sample for inhalation. They have advised that consumers who use a contaminated product are at risk for serious, potentially life-threatening infections. Those at higher risk include young children, elderly people, pregnant women and individuals with a weakened immune system.
FDA has advised that they have not evaluated or approved PNC-27 as safe and effective to treat any disease, including any form of cancer. The agency has also advised that they have not received reports of illnesses or serious adverse events related to PNC-27. It is recommended that patients with cancer discuss their suitable treatment options with a licensed health care professional. Those who have used any PNC-27 products and have concerns should contact their health care provider as soon as possible.
The FDA is encouraging all health care professionals and patients to report any adverse events or side effects related to the use of PNC-27 to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program online or call 1-800-3321088.
Have you or someone you know used PNC-27? Get in touch with us at [email protected] to tell us about your experience!